

**SCYL1 Antibody (N-term) Blocking Peptide**

Synthetic peptide

Catalog # BP7215a

**Specification**

---

**SCYL1 Antibody (N-term) Blocking Peptide - Product Information**

Primary Accession

[Q96KG9](#)**SCYL1 Antibody (N-term) Blocking Peptide - Additional Information**

Gene ID 57410

**Other Names**

N-terminal kinase-like protein, Coated vesicle-associated kinase of 90 kDa, SCY1-like protein 1, Telomerase regulation-associated protein, Telomerase transcriptional element-interacting factor, Teratoma-associated tyrosine kinase, SCYL1, CVAK90, GKLP, NTKL, TAPK, TEIF, TRAP

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP7215a](/product/products/AP7215a) was selected from the N-term region of human SCYL1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**SCYL1 Antibody (N-term) Blocking Peptide - Protein Information**

Name SCYL1

Synonyms CVAK90, GKLP, NTKL, TAPK, TEIF, TRAP

**Function**

Regulates COPI-mediated retrograde protein traffic at the interface between the Golgi apparatus and the endoplasmic reticulum (PubMed: [18556652](http://www.uniprot.org/citations/18556652)). Involved in the maintenance of the Golgi apparatus morphology (PubMed: [26581903](http://www.uniprot.org/citations/26581903)). Has no detectable kinase activity in vitro (PubMed: [18556652](http://www.uniprot.org/citations/18556652)).

**Cellular Location**

Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Endoplasmic reticulum-Golgi intermediate compartment Golgi apparatus, cis-Golgi network Note=Localized to the Endoplasmic reticulum-Golgi intermediate and cis- Golgi in an ARF1-independent manner [Isoform 2]: Cytoplasm. Note=Cytoplasmic throughout the cell cycle [Isoform 6]: Nucleus

**Tissue Location**

Ubiquitous..

**SCYL1 Antibody (N-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**SCYL1 Antibody (N-term) Blocking Peptide - Images****SCYL1 Antibody (N-term) Blocking Peptide - Background**

SCYL1 forms multimers following transfection into COS-7 cells. SCYL1 forms a 300-kD trimer using crosslinking reagents. Biochemical analysis revealed no phosphorylation or autophosphorylation activity. The 707-amino acid SCYL1 variant, variant 2, localized to centrosomes during mitosis. During interphase, fluorescence-tagged variant 2 localized in the cytoplasm as well as centrosomes. However, at the beginning of mitosis, the fluorescence appeared as a pair of bright nuclear foci that followed centrosome localization throughout mitosis, while maintaining diffuse cytoplasmic labeling. Endogenous variant 2 in HeLa cells showed a similar staining pattern. Centrosomal localization was independent of microtubules.

**SCYL1 Antibody (N-term) Blocking Peptide - References**

Tang, Z., et al., Biochem. Biophys. Res. Commun. 324(4):1324-1332 (2004). Kato, M., et al., Genomics 79(6):760-767 (2002). Liu, S.C., et al., Biochim. Biophys. Acta 1517(1):148-152 (2000). van Asseldonk, M., et al., Genomics 66(1):35-42 (2000).